Predictive value and changes of inducible nitric oxide synthase expression in patients with rectal cancer under the influence of antitumor therapy
DOI:
https://doi.org/10.14739/2310-1237.2018.2.141349Keywords:
inducible nitric oxide synthase, rectal cancer, pathology, chemotherapy, radiotherapy, L-arginine, tegafurAbstract
The aim of investigation – to establish the features of iNOS expression in the rectum wall under the influence of various neoadjuvant therapy options in patients with rectal cancer (RC) and to find out its predictive significance.
Materials and methods. In 88 patients with stage II–III rectal adenocarcinoma we established iNOS expression in the tumor before and after neoadjuvant radiotherapy (NRT), therapeutic pathomorphosis grade and density of immune cell infiltrates. Patients were divided into 3 groups: 1 – patients after the course of NRT on the tumor site; 2 – patients who underwent chemoradiomodification of the NRT with drug tegafur; 3 – patients who underwent chemoradiomodification of the NRT with tegafur and L-arginine.
Results. In the tumors of rectal cancer the level of iNOS expression by 4.5 times exceeded that in the intact rectum wall (P < 0.001), correlated with metastatic lesion of the regional lymph nodes (r = 0.55; P = 0.026) and depended on the type of growth of RC. The level of iNOS expression in the tumor prior to treatment in Group 3 patients, in which the high efficacy of NRT was reported, was 54.61 ± 3.55 versus 35.10 ± 2.28 СU in the rest of the patients (P = 0.01). After NRT, most Groups 1–2 patients reduced the iNOS expression in the RC tissue – on the average to 37.30 ± 4.13 СU, more in the residual parenchyma as compared to the tumor stroma, while Group 1 patients showed the lowest total immunosensitivity intensity of iNOS – 24.34 ± 3.10 CU, and Group 3 patients – the highest – 45.35 ± 5.84 CU.
Conclusions. After the use of NRT, iNOS expression in the residual parenchyma of the RC decreased, but in the stroma the marker expression remained unchanged or there was an increase in the marker expression, which was most inherent to therapeutic pathomorphosis grades III–IV. iNOS expression in the RC stroma was highest in patients after NRT with radiomodification using tegafur and L-arginine and positively correlated with the density of immune cell infiltrates in the tumor. Evaluation of the preoperative level of iNOS in patients with RC can serve as a predictive test of advisability of NRT used on the background of radiomodification with L-arginine.
References
Bonavida, B. (Ed) (2015). Nitric Oxide and Cancer: Pathogenesis and Therapy. Los Angeles. doi.org/10.1007/978-3-319-13611-0.
Huerta, S., Chilka, S., & Bonavida, B. (2008). Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol, 33(5), 909–27. doi.org/10.3892/ijo_00000079.
Choudhari, S. K., Chaudhary, M., Bagde, S., Gadbail, A. R., & Joshi, V. (2013). Nitric oxide and cancer: a review. World J Surg Oncol, 11, 118. doi: 10.1186/1477-7819-11-118.
Wink, D. A., Hines, H. B., Cheng, R. Y., Switzer, C. H., Flores-Santana, W., Vitek, M. P., et al. (2011). Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol, 89(6), 873–91. doi: 10.1189/jlb.1010550.
Blaise, G. A., Gauvin, D., Gangal, M., & Authier, S. (2005). Nitric oxide, cell signaling and cell death. Toxicology, 208(2), 177–92. doi.org/10.1016/j.tox.2004.11.032.
Stuehr, D. J. (2004). Enzymes of the L-arginine to nitric oxide pathway. J Nutr, 134 (10 Suppl), 2748S–2751S; discussion 2765S–2767S.
Grimm, E. A., Sikora, A. G., & Ekmekcioglu, S. (2013). Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res, 19(20), 5557–5563. doi.org/10.1158/1078-0432.ccr-12-1554.
Rahat, M. A., & Hemmerlein, B. (2013). Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol, 4, 144. doi: 10.3389/fphys.2013.00144.
Zafirellis, K., Zachaki, A., Agrogiannis, G., & Gravani, K. (2010). Inducible nitric oxide synthase expression and its prognostic significance in colorectal cancer. APMIS, 118(2), 115–24. doi: 10.1111/j.1600-0463.2009.02569.x.
Gochman, E., Mahajna, J., Shenzer, P., Dahan, A., Blatt, A., Elyakim, R., & Reznick, A. Z. (2012). The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem, 114(8), 827–35. doi: 10.1016/j.acthis.2012.02.004.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
